# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

> **NCT07487376** · PHASE1 · NOT_YET_RECRUITING · sponsor: **iBio, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Overweight , Obesity

## Interventions

- **DRUG:** IBIO-600
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07487376
- **Lead sponsor:** iBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07487376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07487376, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07487376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*